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with the terms “EQ-5D”, “SF-36”, “SF-12” and “SF-6D”. RESULTS: The initial search
revealed 5745 publications, 227 of which referring to the HR-QoL questionnaires, of
whom 209 were considered as relevant . Of these, 69 publications were proposed
study protocols in which 31 announced to evaluate CE as an outcome value.
Amongst the remaining 140 papers, 34 were reporting on a new technique, an
alternative questionnaire or on HR-QoL without referring to CE, and 33 were re-
porting on pharmacology or HTA. This results finally in 73 research reports regard-
ing care programs. In only 5 (7%) of them CE has been evaluated, in which 4 by
comparing direct costs and 1 by using QALY’s as outcome value. CONCLUSIONS:
While longitudinal care programs for chronically ill implicate the use of many
health care workers and labour cost is known to count heavily on the budget, CE is
until now, almost never evaluated. Although CE can obviously not be claimed to be
the single important criterion, it is a promising evolution to notice that many study
protocols in this field also aspire after this outcome value.
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EVALUATION OF REAL LIFE USE OF SUGAMMADEX FOR DECURARIZATION OF
NEUROMUSCULAR BLOCKADE IN SURGICAL INTERVENTIONS IN BELGIUM
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OBJECTIVES: Sugammadex is registered for decurarization of moderate/deep neu-
romuscular blockade induced by rocuronium or vecuronium. The advantages com-
pared to the well-known decurarization drugs like neostigmine is that undesirable
side-effects (bradycardia-bronchoconstriction-hypersalivation-nausea-vomiting)
are avoided and deeper levels of blockade can be reversed. In Belgium its reim-
bursement is restricted to certain conditions (impossible intubation or rapid decu-
rarization of deep blockade when medically required or rapid decurarizaton mod-
erate blockade in patients with obstructions (stomach/bowel, bile duct, urinary
tract) or when administration of neostigmine is contra-indicated). The objective of
this study was to evaluate Belgian real-life use of sugammadex one year after
reimbursement was granted.METHODS: The medical records of 330 adult patients
being treated with sugammadex during the first half year of 2011 (6 hospitals se-
lecting 55 consecutive patients) were retrospectively reviewed. Data collection in-
cluded baseline patient-characteristics, hospital-, surgery- and sugammadex-re-
lated info. In addition, a 2-round expert-panel among 12 physicians was organized.
RESULTS: Based on the expert-panel (in combination with published data), it was
estimated that in Belgium rocuronium is used in about 58,100 surgical interven-
tions per year. Reversal with sugammadex is performed in 21.5% of them. Mean age
of the patients using sugammadex was 54 years (/ 17 SD), 45% of the patients
belonged to ASA (American Society of Anesthesiologists) category I-II (healthy-
mild systemic disease), 33% to categoryIII, 84% had co-morbidities. Sugammadex
is mainly used after gastroenterological surgery (53%; high contribution of bariat-
ric-surgery), followed by gynaecological interventions (12%), estimates confirmed
by the expert-panel. According to the experts, in 29% of the patients reversal with
sugammadex was used outside the reimbursement conditions. CONCLUSIONS:
The study confirms that, in Belgium, sugammadex is used when medically needed,
a substantial part being used outside the reimbursement conditions.
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OBJECTIVES: To propose a prospective payment method for the public Health Cen-
ters (HC) in Greece, based on the reimbursement method of Ambulatory Patient
Groups (APG). METHODS: In the absence of electronic patient records, imple-
mented International Classification of Diseases and Current Procedural Terminol-
ogy coding systems, an updated costing system and given that HC in Greece pro-
vide a quite low bundle of services the methodology of the study was accordingly
adjusted. The services provided by the HC were grouped and classified in a few
distinct groups and evaluated by a Delphi panel according to their usability, coher-
ence and technology and labor resource use. According to each groups resource
use, a corresponding labor and technology weight was estimated. An expert panel
estimated the percentage contribution of labor and technology cost in the payment
of each group. The average cost of visit in the HC was used as a base rate. A
mathematical model employed these parameters and provided an estimation of
each group’s payment. Model’s results and parameters were evaluated and ad-
justed to a second expert panel recommendations. APGs’ packaging and discount-
ing techniques were applied. RESULTS: Sixteen groups were created and priced as
follows: Emergency Management (102.6€), Acute Case Management (64.7€), Follow up/
Revisit for an urgent/emergency problem (29.5€), Complete Health Evaluation (48.1€),
Partial Health Evaluation (39.6€), Regular consultation of healthy individual (34.9€),
Laboratory tests (100.8€), Prescription/simple repetition (4.7€), Prescription of drugs/
laboratory tests with Basic medical exam (18.7€), Simple diagnostic/therapeutic pro-
cedure (26.9€), Complex diagnostic/therapeutic procedure (57.6€), Immunization
(23.5€), Primary Prevention/Health education (24.7€), Complex preventive procedure
(39.8€), Physical medicine/Rehabilitation/Counseling/Psychotherapy/Social support
consultation (29.1€), Administrative procedure (12.8€). CONCLUSIONS: Despite the
limitation imposed by the health system’s infrastructure, the current study is es-
timated that can provide a viable reimbursement method and a starting point for
the development of a more detailed method in the future.
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OBJECTIVES: Describe and analyze recent changes in the French drug market ac-
cess in which a dramatic shift in practice is undergoing and impacted by two laws
entered into force in December 2011. METHODS: Literature review was performed
to provide core understanding of the current and future trends in French drug
market access to anticipate its impact for pharmaceutical industry. RESULTS: Con-
dition severity used to be main driver of reimbursement level is now replaced by
drug efficacy criterion. Moreover, the effect size requested for acknowledging drug
innovation has substantially increased. Perceived evidence might also be more
important than actual evidence. Currently, the French National Authority (HAS) is
working on a new therapeutic index that will drive the pricing and reimbursement.
Comparative evidence and real world data are pointed as critical, conditioning
marketing authorization, and will be increasingly requested at the light of the new
drug safety law n.2011-2012. Moreover, within this new legal framework there is a
reinforcement of the regulation about conflicts of interest, a much closed regula-
tion of off-label prescription and early entry of drugs as well as a wide promotion of
generic drugs. The new social security funding law n.2011-1906 pursues the cost
containment measures to control health insurance expenses. This law includes the
Economic and Public Health Assessment Committee (CEESP) in the social security
code. CEESP, that will operate independently of the Transparency Committee, is in
charge of health economics evaluation to determine the most efficient therapeutic
strategies and edit recommendations for decision makers. CONCLUSIONS: French
drug market access will be more and more driven by comparative cost-effective-
ness data and post-marketing studies. Companies will need to anticipate these
requirements during the drug development. However in France, there exists little
or no culture of using health economics for decision making and rather resistance
to it.
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OBJECTIVES: Pricing regulation in Japan is thought to be conservative, however
over the last years, an acceleration of pricing regulation changes has occurred. We
propose to review the dramatic pricing regulation changes that have occurred
especially in 2012. METHODS: Collection and analyses of changes have been per-
formed through literature review of public sources and key opinion leader’s
interviews. RESULTS: One of the main changes concerns pediatric indication that
will now induce premium price for drugs from 5% to 20%, conditional to substantial
efforts from pharmaceutical companies, including studies in Japan and pediatric
formulations. Then, usual cost plus calculation, using the last year as reference for
production, labor, distribution costs etc., will now use the average of the previous 3
years to minimize inflation. International reference pricing have been reviewed to
minimize the cost impact on NHS. As for generics, although they doubled in vol-
ume and value over the last 10 years, they progress slowly: in 2011, generic market
was 23% in volume and 9.5% in value. To counter this, doctors are now eligible for
generic prescription incentive and high co-payment on brand appears to be the
way forward to support generic uptake. Prescription form has been reviewed to
ease request for generic substitution. Generics are priced between 30% discount
down to 46% discount at the maximum. In parallel, enantiomer drugs will now be
discounted by 20% over racemates. This will put them close to generic price (30%
discount). However, opportunities for re-pricing up products were closed to pre-
vent orphan drugs from expanding indication market size and later revenue. Fi-
nally, high drug costs will be excluded from reimbursement through a process
based on drug price distribution to secure convergence toward mean price.
CONCLUSIONS:Despite apparent peace and resistance to changes, Japan market is
also undergoing dramatic changes.
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OBJECTIVES: Radiologists claim that performing two or more CT scans in succes-
sion is rarely necessary, yet the practice of multiple CT scanning during the same
visit has continued in recent years. The objective of this study is to review the
evidence and identify factors contributing to this practice. METHODS: The retro-
spective study included patients from the US Medicare 2009 hospital database.
Over 6 million outpatient claims with the following information were extracted:
patient demographics, hospital characteristics, CT scans hospital charges and
body parts associated with CT scan administration. Multi-level logistic mixed ef-
fects regression was conducted to identify significant factors associated with the
overuse of CT scans among US hospitals. RESULTS: There were 690,643 Medicare
patients that received multiple CT scans during a hospital outpatient visit in 2009.
More than 664 hospitals that administered at least two scans on more than 30% of
their Medicare outpatients. The national average was 5.4%. The figures show wide
variation among states as well, from about 5% in Maryland to almost 23% in Okla-
homa. After multivariable adjustment, female patients had a lower incidence rate
of CT scan overuse (odds ratio, 0.850; 95% CI, 0.847 to 0.851, p0.0001). Rural hos-
pitals tend to practice more CT scan overuse (odds ratio, 1.835; 95% CI, 1.670 to
2.016, p0.0001) than urban hospitals. Hospital charged patient costs of CT scans
also tend to vary across regions. CONCLUSIONS: There is strong statistical evi-
dence that US hospitals practice of CT scan overuse continued in 2009 based on the
Medicare outpatient population. While the study is subject to limitations, it cor-
roborates with previous policy studies that hospitals can and should do more to
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change physician behavior by implementing new protocols and continue to mon-
itor ongoing administrations of multiple CT scans. The study also warrants poten-
tial investigation of similar European hospital databases.
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STAKEHOLDERS’S VIEWS ON RECENTLY INTRODUCED MEASURES TO
PROMOTE GENERICS CONSUMPTION IN GREECE
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OBJECTIVES: The economic crisis has led Greece to adopt measures towards re-
ducing public pharmaceutical expenditure. One of the most important key sectors
addressed was that of the market share of generics. The aim of the study was to
evaluate stakeholder’s perceptions of the recently introduced or planned pharma-
ceutical policy reforms regarding generics policy in Greece. METHODS: A qualita-
tive study, using the method of semi-structured interviews was conducted. We
identified 24 decision makers and opinion leaders from public and private organi-
zations, after developing an influence map. In total 17 interviews were conducted,
using an open-ended questions guide. The interviews were tape recorded, tran-
scribed and content analyzed. RESULTS: The majority of stakeholders perceived
the prices of generics as “high” and “non-competitive” and their pricing system as
problematic, also highlighting the lack of incentives for increased use of generics
that results in low penetration in the market. An important issue strongly empha-
sized was the introduction of stricter audit and quality control mechanisms. Re-
garding INN prescribing, stakeholders appeared to be skeptical for both its effec-
tiveness and its viability, as concerns focusing on the maturity of the system, on
the culture and education of the physicians and on the lack of monitoring mecha-
nisms, cannot guarantee its effective implementation. CONCLUSIONS: There is
general agreement that a generics policy in Greece should aim at having low prices
and higher generic penetration in the market, by introducing incentives for all
stakeholders as well as ensuring the quality and safety of generics. The introduc-
tion of INN was not clearly deemed as a measure that can assist to achieve the goal
of containing pharmaceutical expenditure. The pricing system of generics has now
been reformed, leading to lower prices. Further policy measures are needed in the
framework of a comprehensive generics policy in order to increase generics con-
sumption.
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OBJECTIVES: Identify differences of biosimilar uptakes across the EU big five:
France, Italy, Germany, UK, Spain, and USA. METHODS: We identified policies and
biosimilars market shares in volume and value in EU big five: France, Italy, Ger-
many, UK, Spain and USA. We browsed websites of EU and national (when appli-
cable) drug agencies, ministries of health, HTA bodies, payers, manufacturer
unions etc. We completed our research with literature search and grey reports, as
well as Datamonitor reports, IMS data and proprietary pharmavitae database.
RESULTS: Contrary to FDA, EMA has a well defined regulatory path for biosimilars.
However, when the US Patient Protection and Affordable Care Act 2010 enters into
force in 2014, the biosimilars market will be boosted. Today 80% of this market is in
EU. While uptakes in Spain and UK have started to increase, Germany and France
account currently for half of the biosimilars market by value in EU with a 36% and
19% share respectively. In UK, biosimilars have had low penetration, and in Italy
the market is far behind other countries. Other countries with apparently high
sales of biosimilars like Greece are source countries for parallel market. Obviously
there is no overlap between the generics market size and the biosimilars one. The
slow uptake versus generics can be explained by the low discount of biosimilar
price versus branded products and the uncertainty about the clinical effect.
CONCLUSIONS: The lack of regulatory path in USA makes difficult the launch of
biosimilars. However, EU is the experimental field where companies develop their
ability to capture this market. Small molecule generics continue representing the
main source of cost savings in Europe. Biosimilars represent a huge opportunity for
cost saving in the future especially in the USA where the biologic market is leader.
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DETERMINANTS OF DRUG THERAPY PROBLEMS AMONG MEDICAID PATIENTS
RECEIVING A TELEPHONIC MEDICATION THERAPY MANAGEMENT PROGRAM
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OBJECTIVES: To examine predictors of drug therapy problems (DTP) among pa-
tients who received a telephonic medication therapy management (MTM)
program. METHODS: Retrospective data was collected from 712 Medicaid patients
who received an initial medication therapy review (MTR) as part of a statewide
telephonic MTM program during an 18-month period. Data was extracted from two
administrative claims files for health care utilization and prescription dispensing
information and one medical record file for MTM program information. For analy-
ses, the main outcome variable was the number of pharmacist-identified DTPs
during the initial MTR. Univariate and multivariate models examined the variables
of age, sex, co-morbid conditions, number of inpatient, outpatient, and emergency
department (ED) visits, number of total, chronic, and narrow therapeutic index
drugs, total medication doses per day, and the number of prescribers and dispens-
ing pharmacies for their relationship with the main outcome. For all medication
and service utilization variables, only data from the three months prior to the MTR
were included. RESULTS: At least one DTP was identified in 61.1% of patients (per
patient mean 22/ 25.) Univariate analyses found that female sex, diagnosis of
hyperlipidemia, number of ED visits, number of total and chronic medications,
total medication doses per day, and the number of pharmacies where patients had
prescriptions filled were significantly (p 0.05) associated with having more DTPs.
In multivariate analyses, female sex, diagnosis of hyperlipidemia, number of ED
visits, and number of total and chronic medications remained as significant pre-
dictors (p0.05) of DTPs. In sensitivity analyses for 10, 20, 30, and 40 or more DTPs
per patient, these variables remained significant predictors in the models except
for number of chronic medications. CONCLUSIONS: Providers and policymakers
planning the implementation of MTM services, particularly for Medicaid patients,
may benefit from considering these findings in defining targeted populations for
service delivery.
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PERFORMING HOSPITALS
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OBJECTIVES: The objective of this paper was to examine the performance of 90
public general hospitals of the Greek National Health System (GNHS) in 2010, rank
hospitals according to their efficiency and identify potentials for input reductions.
Additionally, the aim of the study was to identify best practices regarding procure-
ment policies for pharmaceuticals and other medical goods used by the most effi-
cient hospitals. METHODS: Data Envelopment Analysis (DEA) was used for the
estimation of efficiency scores. The number of beds, doctors, management and
nursing personnel and total hospital expenditures were used as inputs and number
of patient admissions, patient days, outpatient visits and surgical interventions as
outputs. In order to identify best practices regarding the efficient performance of
the leading hospitals, a panel of academic experts and executives of the three top
performing hospitals, was used. RESULTS: The results show that only 31% of Greek
hospitals are efficient, with a mean efficiency score of 85.5%. Among hospitals with
the highest efficiency scores (100%) were two University hospitals and one private-
non profit hospital. All three hospitals managed on average, an 11.6% decrease in
pharmaceutical expenditure and 20.1% in the procurement of orthopaedics-pros-
thetics and other medical goods compared to the previous year. At the same time,
the number of admissions increased on average by 8.1% and the number of surgical
interventions also increased in to hospitals by more than 2%. Regarding the best
practices used, the experts agreed that among the most effective procurement
policies are tendering and renegotiation with a number of suppliers. Additionally,
they all agreed that the introduction of e-procurement decreased pharmaceutical
and other medical goods consumption. CONCLUSIONS: If the GNHS was to elimi-
nate inefficiency it could save up to 208.5 million euro or 10.3 % of the total budget
allocated to public hospitals in 2010.
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OBJECTIVES: In difficult economic periods policymakers implement cost-contai-
ment measures in the specialty care. Therefore hospital managers have to improve
the technical efficiency of operation. In Hungary merger of hospitals were initiated
to take advantage of economies of scale. Our objective was to assess whether the
merger of the Clinical Center of University of Pecs and the Hospital of Baranya
County in 2010 improved the sustainability and technical efficiency of these
institutions. METHODS: Our analysis was based on data from the controlling sys-
tem of these institutions. We compared revenues, costs, number of cases and
performance data before (2009) and after the merger (2011). RESULTS: After the
merger the National Health Insurance Fund Administration (NHIFA) cut the per-
formance volume limit (PVL) of the institution by 11,7%. This resulted in a reduc-
tion of patient volumes and revenues. The number of cases decreased differen-
tially: it fell by 9,2% on those departments that were previously operated parallel by
both institutions, and only by 2,7% on those department that were earlier only
operated by the Clinical Center. The total bed utilization rate also declined by 6,2%.
The management of the Clinical Center could reduce the operational costs by 958
million HUF by decreasing the number of staff and renegotiating supply contracts.
However due to the decreasing PVL the cost/DRG increased from 136’600 to 149’600
HUF/DRG. CONCLUSIONS: The management of the hospitals applied ceteris pari-
bus assumptions when predicting the outcomes of merge prior to the decision.
NHIFA implemented serious cost-containment measures as a consequence of the
economic crisis. Despite of significant reduction in operational costs, the technical
efficiency of the Clinical Center declined. The institution could not properly adapt
to the loss of revenue caused by the PVL reduction after the merger. In difficult
economic period the ceteris paribus assumption has to be supplemented with
scenario analysis.
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OBJECTIVES: However, the number of disabled pensioner under and in normal
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